GlassScriptPhysician profile
Saarik Chander Gupta
NPI 1790217164
$25,080.29
in general payments reported to CMS, 2019-2025
25 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $226 · 2021: $3,476 · 2022: $2,006 · 2023: $7,125 · 2024: $925 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $7,606 · Education: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,222.59 |
| Travel and Lodging | $7,606.12 |
| Education | $443.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,499.75 | 2021-2025 | Ensite, Ensite Precision, Aveir |
| Medtronic, INC. | $6,618.04 | 2021-2025 | Affera Mapping System, Micra, Corevalve Evolut R |
| Biotronik INC. | $2,861.72 | 2022-2025 | Acticor 7 Vr-T Dx, Pk Papyrus, Orsiro Mission |
| Boston Scientific Corporation | $2,390.75 | 2021-2025 | General - Therapies, Farapulse, Watchman Flx |
| Biosense Webster, INC. | $1,451.82 | 2022-2025 | Carto 3, Na |
| Philips North America LLC | $618.11 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $426.85 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $198.58 | 2020-2025 | Verquvo |
| Shockwave Medical, INC | $155.78 | 2022 | |
| Abiomed | $134.43 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $125.34 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $106.09 | 2023 | Opsumit |
| Genentech USA, INC. | $99.99 | 2019 | |
| Edwards Lifesciences Corporation | $92.32 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.01 | 2025 | Lifevest |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.85 | 2025 | |
| Amgen INC. | $37.26 | 2025 | Repatha |
| Inspire Medical Systems, INC. | $32.50 | 2025 | Inspire |
| Novo Nordisk INC | $26.34 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $24.81 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $19.32 | 2025 | Attruby |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.25 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $17.87 | 2025 | Tryvio |
| E.R. Squibb & Sons, L.L.C. | $16.99 | 2025 | Camzyos |
| Baxter Healthcare | $15.52 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saarik Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.